Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia

Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia

Objective To evaluate the efficacy and safety of antidepressant augmentation of antipsychotics in schizophrenia. Methods Systematic literature search (PubMed/MEDLINE/PsycINFO/Cochrane Library) from database inception until 10/10/2017 for randomized, double‐blind, efficacy‐focused trials comparing ad...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Acta psychiatrica Scandinavica 2018-03, Vol.137 (3), p.187-205
Hauptverfasser: Galling, B., Vernon, J. A., Pagsberg, A. K., Wadhwa, A., Grudnikoff, E., Seidman, A. J., Tsoy‐Podosenin, M., Poyurovsky, M., Kane, J. M., Correll, C. U.
Format: Artikel
Sprache:eng
Schlagworte:
Antidepressants
antidepressives
Antipsychotics
Clinical trials
Double-blind studies
Emotional behavior
Mental disorders
Panic attacks
Patients
psychopharmacology
psychosis
Psychotropic drugs
Schizophrenia
treatment
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective To evaluate the efficacy and safety of antidepressant augmentation of antipsychotics in schizophrenia. Methods Systematic literature search (PubMed/MEDLINE/PsycINFO/Cochrane Library) from database inception until 10/10/2017 for randomized, double‐blind, efficacy‐focused trials comparing adjunctive antidepressants vs. placebo in schizophrenia. Results In a random‐effects meta‐analysis (studies = 42, n = 1934, duration = 10.1 ± 8.1 weeks), antidepressant augmentation outperformed placebo regarding total symptom reduction [standardized mean difference (SMD) = −0.37, 95% confidence interval (CI) = −0.57 to −0.17, P 
ISSN:0001-690X
1600-0447
DOI:10.1111/acps.12854